Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8% – Here’s What Happened

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) dropped 8% during trading on Thursday . The stock traded as low as $21.79 and last traded at $21.86. Approximately 2,687,463 shares changed hands during trading, a decline of 8% from the average daily volume of 2,915,662 shares. The stock had previously closed at $23.77.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company press release & webcast: Sarepta presented the initial Phase 1/2 results showing muscle exposure, biomarker activity and favorable tolerability for SRP‑1001 and SRP‑1003 — the catalyst for the sharp rally as investors price in potential new rare‑disease franchises. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Market reaction & analyst upside: Media and research notes highlighted the data as meaningful proof‑of‑concept for muscle delivery, driving heavy volume, option buying and multi‑day share gains; some outlets and analysts raised upside forecasts. Zacks: SRPT Soars
• Positive Sentiment: Broker upgrades / price‑target hikes from some firms (e.g., Morgan Stanley coverage mentioned by market outlets) amplified bullish sentiment and likely supported the spike. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Elevated options and volume: Unusually large call buying and above‑average trading volume indicate speculative / speculative‑to‑directional positioning that can amplify moves on news. (No article link)
• Neutral Sentiment: Valuation/expectations story: Several analyses caution that the stock’s rebound complicates valuation — analysts note big upside if programs progress, but emphasize early‑stage risk and thin long‑term revenue visibility. Yahoo Finance: Valuation After siRNA Results
• Neutral Sentiment: Conference call / transcript coverage available — useful for digging into biomarker magnitude, safety details and next steps, but does not yet resolve clinical or commercial risk. Seeking Alpha: Transcript
• Negative Sentiment: Analyst skepticism and cautionary takes: Some analysts and commentators say it’s “too early to get excited” — warning that small early cohorts, surrogate biomarker signals and uncertain clinical benefit require more data before re‑rating the company. Seeking Alpha: Too Early To Get Excited
• Negative Sentiment: Mixed analyst actions: Citigroup raised its price target modestly to $13 but kept a sell rating (signals downside vs. rally levels), and Needham reaffirmed an underperform/negative view — these keep short‑to‑medium‑term selling pressure possible if follow‑up data or guidance disappoints. Benzinga: Analyst Notes

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SRPT. Oppenheimer reissued an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Mizuho increased their price target on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Finally, Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a research report on Tuesday, March 3rd. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Trading Down 9.2%

The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -2.55, a PEG ratio of 0.28 and a beta of 0.42. The company has a fifty day moving average of $18.70 and a 200-day moving average of $19.96.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. Sarepta Therapeutics’s revenue was down 32.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 EPS. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the business. Yousif Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company’s stock worth $541,000 after buying an additional 481 shares in the last quarter. Arizona State Retirement System raised its holdings in Sarepta Therapeutics by 2.8% in the 3rd quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock valued at $504,000 after acquiring an additional 717 shares during the last quarter. Sound View Wealth Advisors Group LLC raised its holdings in Sarepta Therapeutics by 6.1% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 728 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 744 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Sarepta Therapeutics by 1.8% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company’s stock worth $829,000 after purchasing an additional 758 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.